Abstract. Transforming growth factor (TGF)-β1 is a profibrotic cytokine that plays a critical role in the progression of diabetic nephropathy (DN). Previous studies have demonstrated that the Smad transcriptional co-repressor, Ski-related novel protein N (SnoN), an antagonizer of TGF-β1/Smad signaling, is downregulated in the kidneys of diabetic rats; however, the underlying molecular mechanisms remain elusive. In the present study, we demonstrated that the upregulation of Smad ubiquitination regulatory factor-2 (Smurf2), through TGF-β1/ Smad signaling, contributes to the downregulation of SnoN under high-glucose conditions in primary human renal proximal tubule epithelial cells (hRPTECs). The hRPTECs were cultured in high-glucose (30 mmol/l D-glucose) medium in the presence or absence of either the proteasome inhibitor, MG132, or the TGF-β type I receptor kinase inhibitor, SB-431542. Small interfering RNA (siRNA) was used to silence Smurf2. The expression levels of SnoN, Smurf2, Smad2 and phosphorylated (p-)Smad2 were measured by western blot analysis and RT-qPCR. The protein levels of SnoN were markedly downregulated, while its mRNA levels were increased in the hRPTECs cultured under high-glucose conditions. The protein and mRNA levels of Smurf2 were significantly increased under high-glucose conditions. The knockdown of Smurf2 increased SnoN expression in the hRPTECs cultured in high-glucose medium. Moreover, MG132 partially inhibited SnoN degradation in the hRPTECs under high-glucose conditions and SB-431542 decreased the phosphorylation of Smad2 and the expression of Smurf2 induced under high-glucose conditions. Taken together, the findings of this study demonstrate that the downregulation of SnoN expression in hRPTECs under highglucose conditions is mediated by the increased expression of Smurf2 through the TGF-β1/Smad signaling pathway.
Introduction
Diabetic nephropathy (DN) is a major microvascular complication of diabetes mellitus (DM) that invariably leads to end-stage renal disease (ESRD). Although DN was traditionally considered a primarily glomerular disease, accumulating evidence indicates that renal tubules play an important role in the pathogenesis of DN (1) (2) (3) . However, the mechanisms through which the deregulation of renal tubules contributes to the development of DN remain largely unknown.
Transforming growth factor (TGF)-β1 initiates intracellular signaling by binding and activating transmembrane type I and II serine/threonine kinase receptors, which in turn activate the downstream mediators, Smad2 and Smad3. Activated Smad2 and Smad3 undergo phosphorylation and heteroligomerize with Smad4 to form the Smad complex, which then translocates to the nucleus to regulate the transcription of TGF-β1 target genes (4, 5) . Under normal physiological conditions, TGF-β1/Smad signaling is tightly controlled by a negative regulatory mechanism. Ski-related novel protein N (SnoN) is a Smad transcriptional co-repressor (6,7) that negatively regulates TGF-β1/Smad signaling by binding and repressing Smad complexes to activate gene transcription (8, 9) . Thus, the abundance and activity of SnoN in a given circumstance may determine the final response of cells to TGF-β1 stimulation. TGF-β1 is a profibrotic cytokine that has been shown to play a key role in the pathophysiology of DN, in both experimental models of DN and in patients (4) . High glucose activates TGF-β1 signaling, which in turn stimulates tubule epithelial cells to overproduce extracellular matrix (10) . A large body of evidence has indicated that TGF-β1 plays a critical role in the development of tubulointerstitial fibrosis in DN (4, (10) (11) (12) . However, the molecular mechanisms underlying the role of TGF-β1 in the pathogenesis of DN remain elusive.
In our previous study, we demonstrated that SnoN protein was downregulated progressively in the kidneys of diabetic
The downregulation of SnoN expression in human renal proximal tubule epithelial cells under high-glucose conditions is mediated by an increase in Smurf2 expression through TGF-β1 signaling XIUJI LI 1, 3 , ZONGLI DIAO 1 , JIAXIANG DING 1 , RUIXIA LIU 2 , LIYAN WANG 1 , WEN HUANG 3 and WENHU LIU rats and primary proximal tubule epithelial cells under highglucose conditions (13) . Moreover, we demonstrated that SnoN inhibited high-glucose-induced epithelial-mesenchymal transition (EMT) in renal tubule cells (13) . These data suggest that the loss of SnoN may lead to tubulointerstitial damage in DN through uncontrolled TGF-β1/Smad signaling. However, the regulatory mechanisms responsible for the decrease in SnoN expression under high-glucose conditions remain to be elucidated. Of note, Smad ubiquitination regulatory factor-2 (Smurf2), an E3 ubiquitin ligase, has been shown to be increased in renal fibrosis induced by obstructive injury and to promote the downregulation of SnoN (14, 15) . Considering that TGF-β1 signaling is commonly upregulated in obstructive nephropathy and DN, we hypothesized that the upregulation of Smurf2 through TGF-β1/Smad signaling may contribute to the downregulation of SnoN in DN.
In this study, we examined the expression of SnoN in human renal proximal tubule epithelial cells (hRPTECs) cultured in high-glucose (30 mmol/l D-glucose) medium in the presence or absence of either the proteasome inhibitor, MG132, or the TGF-β type I receptor inhibitor, SB-431542. We further determined the protein levels of SnoN following the silencing of Smurf2 by small interfering RNA (siRNA) in the hRPTECs under high-glucose conditions.
Materials and methods
Cell culture. The hRPTECs were purchased from ScienCell Research Laboratories (San Diego, CA, USA). The cells were cultured in fibronectin-coated flasks using epithelial cell medium (ScienCell Research Laboratories) supplemented with growth additives, 2% fetal bovine serum (FBS) and penicillin/streptomycin. The cells were cultured at 37˚C in a humidified incubator in the presence of 5% CO 2 . Actively proliferating hRPTECs at the third passage were used in the subsequent experiments.
Cell treatments. When the cells reached 60-80% confluence, the culture medium was replaced with serum-free epithelial cell medium and the cells were starved for 16 h to synchronize cell growth. The cells were incubated in media containing various concentrations of glucose: normal glucose (5. Gene silencing by siRNA. To facilitate the optimization of lipid-mediated transfection for RNA interference (RNAi) experiments, BLOCK-iT™ Alexa Fluor ® Red Fluorescent Control (Invitrogen, Carlsbad, CA, USA), an Alexa Fluor ® 555-labeled, double-stranded RNA (dsRNA) duplex were transfected into the hRPTECs according to the manufacturer's instructions. The transfection efficiency was roughly determined by calculating the ratio of red fluorescence cells among the total cells. Subsequently, the hRPTECs were transiently transfected with negative control siRNA (Cat. no. 12935200), Smurf2 siRNA-1 (ID#VHS41440), or Smurf2 siRNA-2 (ID#VHS41441; Invitrogen) using Lipofectamine RNAiMAX reagent according to the manufacturer's instructions (Invitrogen). Briefly, the cells were plated into 6-well plates in medium without antibiotics and grown to 50-60% confluence at the time of transfection. The siRNAs and Lipofectamine RNAiMAX reagent were diluted in Opti-MEM I reduced serum medium (Invitrogen), separately. The diluted siRNA was then added to the diluted Lipofectamine RNAiMAX reagent and incubated at room temperature for 5 min. The final concentration of siRNA in the medium was 20 nM. The cells were incubated in serumfree medium with siRNA-lipid complex for 6 h at 37˚C. The medium was then replaced with medium with or without 30 mmol/l D-glucose, and the cells were incubated for an additional 48 h. The control cells refer to the untransfected cells cultured for 48 h cultured under high-glucose conditions. The mock-transfected cells refer to the cells cultured for 48 h in media containing high glucose and diluted transfection reagent.
Western blot analysis. Total protein from the cultured cells was extracted using RIPA lysis buffer containing phosphatase inhibitors and protease inhibitors (Roche, Mannheim, Germany). Protein concentrations were determined using the bicinchoninic acid (BCA) assay. Equal amounts of proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore Corp., Bedford, MA, USA). The membranes were blocked in 5% non-fat milk for 1 h and incubated with primary antibody at a dilution recommended by the manufacturer overnight at 4˚C. The primary antibodies used were as follows: anti-Smad2 (ab40855), antiphospho-Smad2 (ab53100; both from Abcam, Cambridge, MA, USA), anti-Smurf2 (sc-25511), anti-SnoN (sc-9141), anti-SnoN (sc-9595) and anti-β-actin (sc-130656; all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). After washing with TBST (10 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% Tween-20), the membranes were incubated for 1 h with horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology, Inc., Boston, MA, USA) at a dilution of 1,3000. The membranes were processed using an enhanced chemiluminescence kit (Millipore Corp.) and the images were captured using the ChemiDoc XRS+ imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). β-actin was used as a loading control. Quantitative analysis of the western blot analysis data was performed by measuring the intensity of the band signals using Image Lab 3.0 software (Bio-Rad Laboratories, Inc.).
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was isolated with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA concentration and quality were determined by spectrophotometry. Complementary (c)DNA was synthesized from 1 µg total RNA using oligo(dT) primers and the Reverse Transcription system (Promega Corp., Madison, WI, USA) at 42˚C for 60 min as recommended by the manufacturer. qPCR with 1 µl cDNA was performed using a TaqMan Gene Expression assay for each mRNA and TaqMan Gene Expression Master Mix (Applied Biosystems, Foster City, CA, USA) in a total of 20 µl/reaction. The PCR conditions were as follows: 95˚C for 10 min, 40 cycles at 95˚C for 15 sec, and 60˚C for 60 sec for amplification. All reactions were performed in triplicate. The results were analyzed using the 2 -ΔΔCt method.
Co-immunoprecipitation.
The hRPTECs were harvested after the cells were cultured in medium containing 30 mmol/l D-glucose for 24 h. The cells were lysed and centrifuged at 12,000 x g for 20 min at 4˚C. The supernatants were collected for immunoprecipitation. After preclearing with normal host IgG (Santa Cruz Biotechnology, Inc.), the lysates were immunoprecipitated overnight at 4˚C with anti-Smurf2 antibody (1/100 µg total protein), followed by precipitation with 20 µl of protein A/G Plus-Agarose (Santa Cruz Biotechnology, Inc.) for 4 h at 4˚C. After 3 washes, the precipitated complexes were separated by 10% SDS-PAGE which was followed by western blot analysis.
Statistical analysis. All data are expressed as the means ± SD. Statistical analysis of the data was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Comparisons among the experimental groups were performed using one-way analysis of variance (ANOVA) followed by Scheffe's test. A value of P<0.05 was considered to indicate a statistically significant difference. (Fig. 1A and B) . This may not be due to the hypertonic pressure of 30 mmol/l D-glucose, as 24.5 mmol/l mannitol, which has an equal osmotic pressure as 30 mmol/l D-glucose, did not apparently alter the abundance of SnoN protein ( Fig. 1A and B) . To determine whether the decrease in SnoN protein expression resulted from the downregulation of SnoN mRNA expression, we measured the SnoN mRNA levels by RT-qPCR. Surprisingly, the SnoN mRNA levels were significantly upregulated in the hRPTECs cultured under highglucose conditions from 12-72 h (Fig. 1C ) in contrast to those of the cells grown in medium containing normal glucose and of high osmolarity. These results indicated that SnoN expression was reduced under high-glucose conditions in the hRPTECs at the post-transcriptional level.
Results
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Smurf2 expression is induced by high-glucose conditions in hRPTECs.
Previous studies have shown that the E3 ubiquitin ligase, Smurf2, targets SnoN for proteasome-mediated degradation (14, 15) . In this study, to determine whether Smurf2 contributes to the downregulation of SnoN under high-glucose conditions, we measured the protein expression levels of Smurf2 in the hRPTECs under high-glucose conditions. Western blot analysis revealed that Smurf2 expression was significantly induced from 24 h in the hRPTECs cultured under high-glucose conditions in a time-dependent manner ( Fig. 2A and B) . RT-qPCR demonstrated the increased mRNA expression of Smurf2 in the hRPTECs cultured under high-glucose conditions from 12 h (Fig. 2C) . Similar to the results observed for SnoN, the hypertonic culture environment did not affect the neither protein expression of Smurf2 ( Fig. 2A and B ) nor its mRNA expression (Fig. 2C) in the hRPTECs. These results demonstrated that the high-glucose conditions enhanced the expression of Smurf2.
Knockdown of Smurf2 by siRNA stabilizes SnoN expression in hRPTECs under high-glucose conditions. Our above-mentioned observations suggest that the upregulation of Smurf2 may contribute to the downregulation of SnoN under high-glucose conditions. To further examine this hypothesis, we first used an RNA interference (RNAi) approach to knockdown Smurf2 expression in the hRPTECs under high-glucose conditions. To ensure the specificity of Smurf2 inhibition, two different doublestranded Smurf2 siRNAs and a control siRNA were separately transiently transfected into the hRPTECs. The transfection efficiency was observed by calculating the ratio of red fluorescent cells among the total cells. Approximately 70-80% of the hRPTECs transfected with siRNA expressed a red fluorescence signal in the nuclei, indicating efficient transfection (Fig. 3A) . The Smurf2 mRNA levels were reduced by 62% following transfection with Smurf2 siRNA-1 and by 45% following transfection with Smurf2 siRNA-2 compared with the cells transfected with the control siRNA (Fig. 3B) . Similarly, the Smurf2 protein levels were reduced by 50% following transfection with Smurf2 siRNA-1 and by 34% following transfection with Smurf2 siRNA-2 compared with the cells transfected with the control siRNA (Fig. 3C) . Subsequently, we examined the SnoN protein levels following the knockdown of Smurf2 expression in the hRPTECs under high-glucose conditions. The Smurf2 protein levels were increased while the SnoN protein levels were decreased when the cells were cultured in high-glucose medium ( Fig. 4A and B) . Following the knockdown of Smurf2 expression, the SnoN protein levels were increased by 1.5-fold in the cells cultured in high-glucose medium, to similar levels observed under normal glucose conditions (Fig. 4B) . These results suggest that high-glucose conditions downregulate SnoN expression by upregulating Smurf2 in the hRPTECs.
Smurf2 physically interacts with SnoN under high-glucose conditions.
To confirm the involvement of the ubiquitinproteasomal degradation pathway in the downregulation of SnoN expression under high-glucose conditions, we used the proteasome specific inhibitor, MG132, to block the ubiquitinproteasomal pathway in the hRPTECs. As shown in Fig. 5A , treatment with MG132 prevented the degradation of SnoN protein in the hRPTECs under high-glucose conditions. We then examined the potential physical interaction between Smurf2 and SnoN in the hRPTECs by protein co-immunoprecipitation. SnoN was detected in the immunocomplexes that were precipitated with Smurf2-specific antibody under high-glucose conditions, while it was undetectable when applied with control IgG or under normal glucose conditions (Fig. 5B) . These results demonstrated that Smurf2 physically interacted with SnoN under high-glucose conditions and suggested that SnoN protein was subjected to proteasome-mediated degradation by Smurf2 in hRPTECs under high-glucose conditions. expression. It has been well documented that TGF-β1 plays a key role in the pathophysiology of DN and that high glucose activates TGF-β1 signaling (4,10). Thus, to determine whether the upregulation of Smurf2 results from enhanced TGF-β1 signaling in the hRPTECs under high-glucose conditions, we treated the hRPTECs under high-glucose conditions with the TGF-β type I receptor specific inhibitor, SB-431542, and examined the expression of Smurf2. The phosphorylation of Smad2, a downstream target of TGF-β1 signaling, was stimulated by high glucose and prevented by SB-431542 (Fig. 6A) , supporting the conclusion that high glucose activates TGF-β1 signaling (4) . Intriguingly, the high-glucose induced increase in the protein levels of Smurf2 was significantly inhibited by SB-431542 in a dose-dependent manner (Fig. 6B) . These results demonstrated that SB-431542 blocked the high-glucose-induced activation of Smad2 and inhibited the protein expression of the Smurf2.
Pharmacological inhibition of TGF-β1 signaling with SB-431542 inhibits high-glucose-induced Smad2 activation and Smurf2
Discussion
In this study, we found that high-glucose conditions decreased the protein level, while increasing the mRNA level of SnoN in the hRPTECs, and concurrently upregulated Smurf2. Moreover, Smurf2 physically interacted with SnoN under high-glucose conditions and the knockdown of Smurf2 by siRNA or MG132 abolished the downregulation of SnoN under high-glucose conditions. Furthermore, the pharmacological inhibition of TGF-β1 signaling with SB-431542 inhibited the high-glucose-induced Smad2 activation and Smurf2 expression. Our findings suggest that the downregulation of SnoN expression in hRPTECs under high-glucose conditions is mediated by an increase in Smurf2 expression through TGF-β1/ Smad signaling.
SnoN is a negative regulator of TGF-β signaling as a consequence of binding to Smad proteins (8, 9) . SnoN disrupts the formation of a functional complex between Smad4 and activated Smad2/3, thereby blocking the Smad complexes from activating the transcription of TGF-β1 target genes (16, 17) . Furthermore, SnoN may recruit other transcriptional co-repressors, such as the nuclear hormone receptor co-repressor (N-CoR), and prevent the binding of Smads to the transcriptional co-activator, p300/ CREB-binding protein (CBP) (6, 8, 17) . These mechanisms may operate together to suppress TGF-β1/Smad signaling through SnoN. On the other hand, Yang et al (18) demonstrated that the threshold for the TGF-β1 response was reduced significantly by the complete depletion of SnoN and that a minimal amount of TGF-β1 was sufficient to trigger a full-scale TGF-β1 response under chronic disease conditions. It is widely accepted that hyperactive TGF-β1 signaling plays a crucial role in the genesis and progression of diabetic renal injuries (11, 12, 19) . Thus, it is possible that the downregulation of SnoN protein expressino under high-glucose conditions may lead to hyperactive TGF-β1/Smad signaling and promote the pathogenesis of DN.
However, the mechanisms that regulate the expression of SnoN are not yet fully understood. SnoN transcription is strongly induced by TGF-β itself (6) . In this study, we demonstrated that the mRNA expression levels of SnoN were significantly increased in the hRPTECs under high-glucose conditions, through an unknown mechanism. This upregulation of SnoN transcription may function as a negative feedback mechanism to inhibit TGF-β1 signaling. Although SnoN mRNA levels were significantly increased, the SnoN protein levels were decreased under these conditions, suggesting that SnoN is mainly regulated at the post-transcriptional level.
Intracellular protein degradation is a tightly regulated process that is essential to sustain normal cellular functions and is mainly controlled by the ubiquitin-proteasome system, which contains an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme, and a substrate specific E3 ubiquitin ligase. The E3 ubiquitin ligase defines the substrate selectivity and the subsequent degradation by the 26S proteasome (20, 21) . As previously demonstrated, the deregulation of the ubiquitinproteasome system disrupts normal cellular homeostasis and leads to the development of a number of human diseases, including Liddle syndrome, ischemic acute renal failure and obstructive nephropathy (14, 15, 20) . Smurf2, homologous to the E6-AP carboxyl terminus (HECT) domain-containing E3 ubiquitin ligase, targets SnoN for ubiquitin-mediated degradation by the proteasomes (22) . In the present study, we demonstrated that SnoN reduction in the hRPTECs, cultured under high-glucose conditions, was mediated by enhanced proteasome-dependent degradation. Firstly, SnoN protein levels were decreased in spite of an increase in its mRNA expression. Secondly, Smurf2 mRNA and protein levels were induced in the hRPTECs cultured in high-glucose medium.
Thirdly, the knockdown of Smurf2 expression by siRNA stabilized the SnoN protein levels in the hRPTECs. Finally, Smurf2 physically interacted with SnoN, and treatment with MG132 restored SnoN expression. Thus, Smurf2 targeting of SnoN for degradation by the ubiquitin-proteasome system is one of the mechanisms responsible for the downregulation of SnoN in hRPTECs under high-glucose conditions. However, other E3 ubiquitin ligases, such as the anaphase-promoting complex and Arkadia, have also been shown to target SnoN for degradation in response to TGF-β1 (23, 24) . Whether they are also involved in the proteasome-dependent degradation of SnoN under high-glucose conditions remains to be determined.
The mRNA expression of Smurf2 is rapidly induced by TGF-β itself (25, 26) . Furthermore, Smurf2 induction by TGF-β1 requires Smad signaling rather than the p38 mitogen-activated protein kinase (MARK), phosphoinositide 3-kinase (PI3K), c-Jun N-terminal kinase (JNK), or MEK signaling pathways (26) . SB-431542 is a potent and specific inhibitor of the TGF-β type I receptor (27, 28) . Inman et al (28) reported that SB-431542 inhibited the TGF-β-induced phosphorylation of Smad2 and blocked the activation of TGF-β signaling. In this study, we found that SB-431542 suppressed the expression of phosphorylated (p-)Smad2 and Smurf2 in a dose-dependent manner. These observations suggest that the upregulation of Smurf2 by TGF-β/Smad signaling contributes to the degradation of SnoN under high-glucose conditions.
In conclusion, in this study, we demonstrated that the downregulation of SnoN expression in hRPTECs under high-glucose conditions is mediated by an incresae in Smurf2 expression through the TGF-β1/Smad signaling pathway. Our findings suggest that a decrease in SnoN expression may eliminate the negative regulatory mechanism for TGF-β1 signaling and amplify profibrotic TGF-β1 signaling, leading to a vicious cycle between Smurf2 expression and TGF-β1 action. The preservation of SnoN by a proteasome inhibitor or by the knockdown of Smurf2, may be an effective approach for confining pathological TGF-β1 activity.
